Evidence map›Paper›PMID 41872691›Full record

ArticleOncogene2026

Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.

Chia-Hui Chen, Ryan Brown, Donald J Vander Griend, Allen C Gao, Boyang Jason Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chia-Hui ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Ryan BrownDepartment of Pathology, The University of Illinois, Chicago, IL, USA.
Donald J Vander GriendDepartment of Pathology, The University of Illinois, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-4421-5698
Allen C GaoDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0002-5966-9038
Boyang Jason WuDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA. boyang.wu@wsu.edu.ORCID http://orcid.org/0000-0002-2823-3573

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of next-generation androgen receptor signaling inhibitors (ARSIs) like enzalutamide (ENZ), has improved the clinical management of castration-resistant prostate cancer (CRPC). However, acquired resistance to these therapies often develops rapidly, and the underlying resistance mechanisms remain largely unclear. Here, we identified the aryl hydrocarbon receptor (AHR) as a crucial operator of ENZ-resistant CRPC. AHR is upregulated in three ENZ-resistant human CRPC cell lines (C4-2B

Indexed as

Basic Helix-Loop-Helix ProteinsDrug Resistance, NeoplasmPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantReceptors, AndrogenReceptors, Aryl HydrocarbonAnimalsBenzamidesCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceNitrilesSignal TransductionXenograft Model Antitumor AssaysAHR protein, humanAR protein, humanBasic Helix-Loop-Helix ProteinsBenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenReceptors, Aryl Hydrocarbon

Identifiers

PMID41872691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.